Streetbeat News

Products Services

HSCS

HeartSciences has been issued a notice of patent allowance from the Brazilian Patent and Trademark Office and the UAE Ministry of Economy, Intellectual Property Protection Department. This could potentially increase the company's market reach and value.

Portfolio Pulse from Bill Haddad

September 26, 2023 | 12:06 pm

BIVI

BioVie Inc. (NASDAQ:BIVI) has completed the last patient treatment visit in its Phase 3 trial of NE3107 for mild to moderate Alzheimer's Disease. The company expects to announce topline data in November/December 2023. The trial's results will be analyzed and submitted to the FDA for review. BioVie's President and CEO, Cuong Do, expressed optimism about the trial's outcome based on previous Phase 2 data.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2023 | 12:06 pm

CUE

Cue Biopharma has completed patient enrollment in its Phase 1 trial of CUE-101 in combination with Keytruda as a first-line treatment for HPV positive recurrent/metastatic head and neck squamous cell carcinoma.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2023 | 12:06 pm

AMC

AMC Theatres (NYSE:AMC) announced that Taylor Swift's record-breaking concert film, 'The Eras Tour', will be shown in more than 100 countries starting October 13. The film will be available at all AMC locations in the US and every ODEON Cinemas location throughout Europe. AMC is working with movie theatre operators worldwide to expand this footprint. The film has already set a record for the highest ticket-sales revenue during a single day in AMC's 103-year history.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2023 | 12:05 pm

TSHA

Taysha Gene Therapies has announced that the second patient has been dosed with TSHA-102 in the REVEAL Phase 1/2 adult trial for the treatment of Rett syndrome. The company expects to complete enrollment in the low-dose cohort in Q4 2023 and to dose the first pediatric patient in Q1 2024. The FDA has cleared the Investigational New Drug application for TSHA-102 in pediatric patients, and the company has submitted a Clinical Trial Application to the UK's MHRA.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2023 | 12:04 pm

CADL

Candel Therapeutics has reported initial survival data from its Phase 2 clinical trial of CAN-2409 in non-small cell lung cancer. The initial data suggests that the 12-month survival is consistent with an increased tail on the maturing survival curve.

Portfolio Pulse from Bill Haddad

September 26, 2023 | 12:03 pm

SRTS

Sensus Healthcare, Inc. (NASDAQ:SRTS) will present its full line of superficial radiotherapy (SRT) devices for the treatment of non-melanoma skin cancer and keloids at the American Society for Radiation Oncology (ASTRO) Annual Meeting in San Diego from October 1-4. The company's devices utilize the Multi-Dimensional Superficial Radiotherapy platform, which provides an alternative low-energy X-ray treatment for various types of non-melanoma skin cancer and keloids.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2023 | 12:02 pm

PHAT

Phathom Pharmaceuticals has announced the submission of a New Drug Application (NDA) for Vonoprazan for the treatment of non-erosive gastroesophageal reflux disease (GERD).

Portfolio Pulse from Bill Haddad

September 26, 2023 | 12:02 pm

KULR

KULR Technology Group, Inc (NYSE:KULR) has signed a Memorandum of Understanding (MOU) with Forge Nano, a global player in precision nano-coating technology. The partnership, estimated to generate $3.5 million - $5 million in revenue, will combine KULR's advanced automated battery cell screening capabilities with Forge Nano's Atomic Layer Deposition (ALD) coating process. The partnership will initially focus on assessing Forge Nano's premium battery cells for space and U.S. Department of Defense (DoD) applications.

Portfolio Pulse from Anusuya Lahiri

September 26, 2023 | 12:02 pm

ONCY

Oncolytics Biotech, Inc. (NASDAQ:ONCY) has been selected by the Pancreatic Cancer Action Network (PanCAN) to receive a $5 million Therapeutic Accelerator Award. The award is in recognition of Oncolytics' work on pelareorep, an investigational immunotherapy treatment for pancreatic cancer. The grant will fund the next stage of research, which includes a clinical trial of pelareorep in combination with modified FOLFIRINOX chemotherapy. If successful, the treatment may advance to late-stage clinical development through the PanCAN Precision Promise adaptive clinical trial platform.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2023 | 12:02 pm